Welcome to our dedicated page for Esperion Therape SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Esperion Therapeutics, Inc. (ESPR) SEC filings page provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Esperion is a commercial-stage biopharmaceutical company listed on the Nasdaq Stock Market LLC under the symbol ESPR, and its filings offer detailed insight into its cardiometabolic and rare/orphan disease business, including oral non-statin LDL-C therapies such as NEXLETOL and NEXLIZET.
Key filing types for Esperion include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s business, risk factors, financial statements, and discussion of operations. Current reports on Form 8-K and 8-K/A, several of which are referenced in the provided data, disclose material events such as financial results, underwritten public offerings of common stock, executive appointments, board changes, and other significant corporate developments.
Investors can also review notifications of late filing on Form 12b-25, which explain delays in periodic reports and provide management’s narrative regarding the status of financial closing procedures. For Esperion, these documents have included explanations related to quarterly financial close and corrections to previously furnished earnings releases.
On Stock Titan, Esperion’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the content of lengthy documents, highlight key sections, and surface items such as revenue drivers, commercialization plans for NEXLETOL and NEXLIZET, capital-raising transactions, and changes in executive leadership. Users can also identify trading symbol information, exchange listing details, and other disclosures related to Esperion’s common stock directly from these filings.
Esperion Therapeutics, Inc. reported preliminary 2025 results and shared expense guidance for the fiscal year ending December 31, 2026. Management currently expects 2026 research and development expenses to range from $40 million to $50 million, selling, general and administrative expenses to range from $170 million to $195 million, and total operating expenses to range from $210 million to $245 million. The figures reflect management’s current expectations and were released in connection with the company’s presentation at the Annual J.P. Morgan Healthcare Conference.
Esperion Therapeutics, Inc. reported an insider stock transaction by its President and CEO, who is also a director. On 12/17/2025, the insider sold 48,244 shares of common stock at $3.673 per share. After this transaction, the insider beneficially owned 1,470,587 shares of Esperion common stock.
The company states that these shares were sold to satisfy tax obligations arising from vested restricted stock units, meaning the sale was tied to covering taxes rather than a discretionary reduction of ownership.
Esperion Therapeutics Chief Financial Officer Sheldon L. Koenig reported a routine stock transaction involving company shares. On 12/17/2025, he sold 7,337 shares of Esperion Therapeutics common stock at a price of $3.667 per share. According to the filing, these shares were sold to cover tax obligations arising from the vesting of restricted stock units. After this sale, Koenig beneficially owned 467,525 shares of Esperion common stock, held directly.
Esperion Therapeutics, Inc. reported an insider stock transaction by its General Counsel. On 12/17/2025, the officer sold 6,517 shares of common stock at a price of $3.667 per share. According to the explanation, these shares were sold to satisfy tax obligations arising from vested restricted stock units, meaning the sale was related to tax withholding rather than a discretionary liquidation of holdings. Following this transaction, the reporting person directly owned 385,905 shares of Esperion common stock.
Esperion Therapeutics, Inc. filed an initial ownership report for a senior executive showing no equity holdings. The filing is a Form 3 for the company’s Chief Commercial Officer, who is classified as an officer of Esperion Therapeutics, Inc. (ticker ESPR). The event date for this ownership status is listed as 11/17/2025. According to the remarks, no securities of Esperion, either direct or derivative, are beneficially owned by this reporting person as of that date.
Esperion Therapeutics (ESPR) reported Q3 2025 results showing stronger top-line momentum but ongoing losses. Total revenue reached $87.3 million, up from $51.6 million a year ago, driven by product sales of $40.7 million (vs. $31.1 million) and collaboration revenue of $46.7 million (vs. $20.5 million). Operating loss narrowed to $10.0 million, but higher interest expense brought net loss to $31.3 million (vs. $29.5 million). Year‑to‑date, revenue was $234.7 million with a net loss of $84.5 million.
Cash and cash equivalents were $92.4 million as of September 30, 2025, with operating cash outflow of $58.3 million year‑to‑date. The balance sheet reflects a royalty sale liability of $294.2 million (interest expense $14.6 million in Q3) and long‑term debt of $151.7 million under a December 2024 credit agreement. Accounts receivable grew to $119.0 million and inventories to $108.5 million, supporting higher sales. The company settled several generic challenges in 2025 and continues defending remaining ANDA cases; certain asserted patents extend into 2040. Shares outstanding were 239,063,437 as of October 31, 2025.
Esperion Therapeutics (ESPR) reported Q3 2025 results showing stronger top-line momentum but ongoing losses. Total revenue reached $87.3 million, up from $51.6 million a year ago, driven by product sales of $40.7 million (vs. $31.1 million) and collaboration revenue of $46.7 million (vs. $20.5 million). Operating loss narrowed to $10.0 million, but higher interest expense brought net loss to $31.3 million (vs. $29.5 million). Year‑to‑date, revenue was $234.7 million with a net loss of $84.5 million.
Cash and cash equivalents were $92.4 million as of September 30, 2025, with operating cash outflow of $58.3 million year‑to‑date. The balance sheet reflects a royalty sale liability of $294.2 million (interest expense $14.6 million in Q3) and long‑term debt of $151.7 million under a December 2024 credit agreement. Accounts receivable grew to $119.0 million and inventories to $108.5 million, supporting higher sales. The company settled several generic challenges in 2025 and continues defending remaining ANDA cases; certain asserted patents extend into 2040. Shares outstanding were 239,063,437 as of October 31, 2025.
Esperion Therapeutics filed a Form 8-K stating it furnished a press release announcing financial results for the three and nine months ended September 30, 2025.
The information under Item 2.02 and Exhibit 99.1 is furnished and not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference under the Securities Act except as specifically referenced.
Esperion Therapeutics filed a Form 8-K stating it furnished a press release announcing financial results for the three and nine months ended September 30, 2025.
The information under Item 2.02 and Exhibit 99.1 is furnished and not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference under the Securities Act except as specifically referenced.
Esperion Therapeutics appointed John B. Harlow, Jr. as Chief Commercial Officer, effective November 17, 2025. The hire adds a veteran commercial leader with prior CCO roles at Melinta Therapeutics and Baudax Bio.
Under his agreement, Harlow will receive a $535,000 base salary, a target bonus equal to 45% of salary, and a $35,000 sign-on bonus. Equity awards include options for 380,000 shares at the grant-date closing price and 424,536 RSUs, each vesting over four years, subject to continued service. Severance provides one year of salary (and, upon a sale event, salary plus target bonus) and COBRA-related cash payments, subject to customary release conditions.
Esperion Therapeutics (ESPR) reported an insider transaction by its General Counsel. On 10/17/2025, the officer sold 1,248 shares of common stock at $2.6245 per share. The filing states the shares were sold to satisfy tax obligations on vested restricted stock units.
Following the sale, the officer directly owned 392,422 shares. This Form 4 reflects a tax-related sale rather than an open-market disposition for investment purposes.
Esperion Therapeutics, Inc. filed an 8-K reporting a material event that centers on a securities offering. The filing references two press releases dated October 7, 2025: one announcing the offering and one announcing the pricing of the offering. The company also disclosed an opinion of Goodwin Procter LLP and the firm's consent (included as Exhibit 5.1). The document includes the interactive data cover page and is signed by Sheldon Koenig, President and Chief Executive Officer on October 8, 2025. The filing shows the offering has been publicly announced and legally documented, but it does not disclose offering size, securities type, or net proceeds.